title: Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.
abstract: Chronic treatment of the laboratory rat with haloperidol results in an increased stereotypic behavioral response to subsequent dopamine agonist challenge. This behavioral hypersensitivity (BH) is thought to reflect an increase in DA receptor number following chronic pharmacologic denervation. Using a cotreatment strategy, we demonstrate here that a variety of agents can attenuate or prevent the development of BH when administered chronically with haloperidol. Cotreatment with lithium and amantadine prevented the changes in DA biochemistry as well as the proliferation of DA receptors normally associated with chronic haloperidol treatment. Cotreatment with thioridazine or scopolamine did alter the changes in DA biochemistry normally associated with haloperidol treatment, but failed to attenuate the DA receptor proliferation. Taken together, these data suggest that mechanisms in addition to DA biochemical and receptor changes participate in the development and subsequent expression of BH. DA receptor proliferation must, therefore, be considered permissive to the development of BH.
authors.affiliation: Department of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, Chicago, IL 60612.
authors.forename: P M
authors.initials: PM
authors.lastname: Carvey
authors.forename: L C
authors.initials: LC
authors.lastname: Kao
authors.forename: T J
authors.initials: TJ
authors.lastname: Zhang
authors.forename: R L
authors.initials: RL
authors.lastname: Amdur
authors.forename: D H
authors.initials: DH
authors.lastname: Lin
authors.forename: R
authors.initials: R
authors.lastname: Singh
authors.forename: H L
authors.initials: HL
authors.lastname: Klawans
mesh_terms: D000547:Amantadine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology*; D008094:Lithium / Q000494:pharmacology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism; D012601:Scopolamine / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000187:drug effects*; D013881:Thioridazine / Q000494:pharmacology
chemical_list: D011954:Receptors, Dopamine; D008094:Lithium; D000547:Amantadine; D012601:Scopolamine; D006220:Haloperidol; D001058:Apomorphine; D013881:Thioridazine; D004298:Dopamine